A new cell therapy approach, referred to as "dual target" or "dual-target", appears to show promise in shrinking brain tumors. The therapy, which involves modified CAR T-cells, may be effective in slowing the growth of aggressive brain cancers, including glioblastoma and pediatric brain tumors. The treatment's effects are being studied, with some reports indicating it may help prevent tumor relapse.